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Abstract
In the epidemiologic context of maternal obesity and 
type 2 diabetes (T2D), the incidence of gestational 
diabetes has significantly increased in the last decades. 
Infants of diabetic mothers are prone to various 
neonatal adverse outcomes, including metabolic and 
hematologic disorders, respiratory distress, cardiac 
disorders and neurologic impairment due to perinatal 
asphyxia and birth traumas, among others. Macrosomia 
is the most constant consequence of diabetes and 
its severity is mainly influenced by maternal blood 
glucose level. Neonatal hypoglycemia is the main 
metabolic disorder that should be prevented as soon 
as possible after birth. The severity of macrosomia and 
the maternal health condition have a strong impact 
on the frequency and the severity of adverse neonatal 
outcomes. Pregestational T2D and maternal obesity 
significantly increase the risk of perinatal death and birth 
defects. The high incidence of maternal hyperglycemia 
in developing countries, associated with the scarcity 
of maternal and neonatal care, seriously increase the 
burden of neonatal complications in these countries.
Key words: Birth defects; Hypoglycemia; Respiratory 
distress; Preterm; Perinatal mortality; Type 2 diabetes; 
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Core tip: Increased mortality and morbidity are histo-
rically attributed to neonates of diabetic mothers. A 
discerning analysis of the literature shows that these 
adverse outcomes are uncommon among infants 
born from “pure” gestational diabetes mellitus (GDM) 
mothers, well managed during pregnancy. Macrosomia 
is the predominant adverse outcome and the main 
factor linked to neonatal complications. Poor maternal 
glycemic control, especially in the context of maternal 
type 2 diabetes and obesity increases the risk of all 
adverse neonatal outcomes, most strikingly the risk 
of perinatal mortality and birth defects. Developing 
strategies for screening and managing women with 
GDM must be encouraged notably in middle and low 
income countries and, also to limit the adverse effects 
on global health population in the future. 
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INTRODUCTION
Gestational diabetes mellitus (GDM) is defined as 
a glucose intolerance of any degree with onset or 
first recognition during pregnancy. In high income 
countries, but also in middle and low income countries, 
because of the spreading of industrialized lifestyle, the 
incidence of obesity and type 2 diabetes (T2D) has 
dramatically increased, and subsequently the incidence 
of GDM[1].
In high-resource countries, progress has been made 
during the past fifty years regarding preconceptional 
care, screening and management of GDM. However, in 
low and middle-income countries, quality of antenatal 
care to detect and manage GDM, are often poorly 
available. As a consequence, the prenatal and neonatal 
burden of GDM may be paradoxically higher in these 
countries, although this point is not well documented[2]. 
Much of the currently available knowledge on the 
consequences of maternal diabetes on the offspring 
has been provided by studies on type 1 diabetes (T1D), 
while the risks related to GDM, which is much more 
frequent, need to be clarified in order to improve and 
to adapt neonatal management[3]. Moreover, extensive 
data suggest that the offspring of diabetic mothers is 
furthermore exposed to an increased risk of developing 
chronic, non-communicable diseases at adulthood[4]. 
Neonatologists are facing first-line this new epide-
miologic setting. This review addresses the currently 
available knowledge on short term consequences of GDM 
in neonates and focuses on situations with increased 
risks of neonatal adverse outcomes. 
SHORT TERM OUTCOMES
Macrosomia
Macrosomia is the most constant complication in GDM. 
The concept of excessive fetal growth is expressed 
either by the word “macrosomia” or by the expression 
“large for gestational age” (LGA). Macrosomia is 
defined by a birth weight (BW) of 4000 or 4500 g 
and more, depending on the authors. However, in 
this definition, gestational age (GA) is not taken into 
account. The term LGA corresponds to a BW ≥ 90th 
percentile or > +2SD (> 97th percentile) for GA. This 
definition allows premature newborns with excessive 
fetal growth to be identified. Macrosomia in newborns 
of diabetic mothers is characterized by excess body 
fat, an increased muscle mass and organomegaly, 
without increase in brain size.
The Pedersen-Freinkel’s hypothesis, expressed 
sixty years ago, suggested that fetal overgrowth is 
related to increased transplacental transfer of maternal 
glucose, which stimulates the release of insulin by fetal 
pancreatic beta cells[5]. Insulin is a major factor of fetal 
growth and it up-regulates the Insulin-like Growth 
Factor (IGF) system, subsequently leading to fetal 
macrosomia. According to this hypothesis, different 
studies have characterized the link between maternal 
glycemia and neonatal macrosomia or fat mass[6,7].
The HAPO study showed a continuous, positive 
association between maternal glycemia, fetal hyper-
insulinism and BW[8]. A linear and continuous rela-
tionship between body fat percentage in newborns, 
maternal glycaemia and fetal insulin levels has been 
found in this study[9]. More recently, other mechanisms 
that may also contribute to fetal overgrowth were 
evoked, like maternal metabolic environment and 
placental modifications[10]. In particular, maternal lipids 
availability and transport to the fetus may be enhanced 
in case of maternal diabetes[11].
Hence, all types of maternal diabetes are risk factors 
for macrosomia. As discussed below, macrosomia is per 
se a cause increased neonatal adverse outcome and 
this point emphasizes the importance of recognizing the 
excess of growth, even in preterm infants. Treatment of 
GDM significantly reduces the rate of macrosomia[12,13].
Preterm birth
A number of studies have reported an increased risk 
of preterm births in case of diabetes. However, data 
are not always available on the respective proportion 
of induced and spontaneous births, considering the 
increased maternal and fetal morbidity of diabetes 
during pregnancy. The benefits of early delivery to 
avoid fetal death or shoulder dystocia must be balan-
ced against the morbidity linked to preterm birth, 
especially the respiratory morbidity.
The link between GDM and spontaneous preterm 
birth is still controversial. Hedderson et al[14] showed 
in a large cohort study that GDM was an independent 
risk factor for spontaneous preterm birth (RR = 
1.42, 95%CI: 1.15-1.77). On the other hand, Yogev 
et al[15] found that the rate of spontaneous preterm 
delivery was not increased in GDM compared to non-
GDM patients. Nevertheless, both studies found a 
relationship between higher glucose values in the oral 
glucose tolerance test (OGTT) or higher mean blood 
glucose levels and preterm birth. 
Metabolic disorders
Hypoglycemia: The link between macrosomia, 
increased cord C-peptide levels that reflects fetal 
insulin secretion, and neonatal hypoglycemia has long 
been known. The data collected by the HAPO study 
confirmed this relationship: neonatal hypoglycemia 
was strongly associated with elevated cord serum 
C-peptide levels[16]. The infant of a diabetic mother is 
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at risk of transient hyperinsulinism, which prevents 
at birth the normal activation of metabolic pathways 
producing glucose and ketone bodies, and causes 
increased glucose consumption by tissues[17].
The exact incidence of hypoglycemia in case of 
maternal diabetes is difficult to assess due to the 
various definitions used for neonatal hypoglycemia 
in the literature. The rate of intravenously treated 
hypoglycemia was reported between 5% to 7% in 
two large studies[18,19]. Comparisons with the risk 
observed in healthy newborns are difficult also because 
monitoring of blood glucose at birth was different 
according to the mother was diabetic or not in most 
of the studies. At last, in many studies, blood glucose 
level in neonates is checked soon after birth, although 
the pathologic significance of low blood glucose levels 
immediately after birth, in the absence of specific 
symptoms, is still questioned. Indeed, an immediate 
fall in blood glucose concentration is observed after 
birth because of the interruption of placental supply, 
reaching a nadir between 1 and 2 h in healthy term 
infants[20]. Normal levels at this period cannot be 
distinguished from abnormal ones in asymptomatic 
infants and the incidence of hypoglycemia is likely to 
be overestimated[21]. From 3 h of age, blood glucose 
then rises spontaneously, even in the absence of any 
nutritional intake, due to the activation of metabolic 
regulatory pathways. Therefore, in the absence 
of abnormal clinical signs, the first blood glucose 
measurement is recommended after the second feed, 
which generally allows infants who cannot manage 
adequate early glucose homoeostasis to be identified[21].
There is currently no consensus on the indications for 
systematic glucose blood monitoring in asymptomatic 
infants born to diabetic mothers. It seems reasonable 
to consider that LGA or growth restricted infants (< 
10th percentile) born to diabetic mother may benefit 
from blood glucose concentration check at 3 to 6 h 
intervals during the first day of life. On the other hand, 
normal-grown infants of mothers with diet-controlled 
GDM should not be monitored[22].
For newborns with no clinical signs, therapeutic 
intervention can be considered starting at a threshold 
value of 0.36 g/L (2.0 mmol/L). Early and frequent 
breastfeeding remains the key in preventing hypo-
glycemia, whatever the infant’s BW, as far as he/she 
is able to feed autonomously. Therefore, infants of 
diabetic mothers should be kept aside their mother, 
in the absence of significant complications requiring a 
transfer to a special care neonatal unit. Even in mildly 
or moderately symptomatic infants with low blood 
glucose levels, sustained breastfeeding, or eventually 
formula supplements should be tried first, provided a 
satisfactory clinical response is obtained[22]. In case the 
infant is unable to feed, an IV glucose supplementation 
(3-6 mg/kg per hour) should be provided at constant 
rate of infusion, in order to avoid rebound hypoglycemia. 
Hypocalcemia: Hypocalcemia can be defined by 
plasma calcium concentration below 2 mmol/L or 
ionized calcium concentration below 1.1 mmol/L, 
regardless of GA or BW. Transient neonatal hypo-
calcemia has been mainly reported in neonates of pre-
gestational insulin dependent- diabetic mothers and 
may be partly related to maternal hypomagnesemia 
and subsequent fetal hypomagnesemia. The severity 
of hypocalcemia also appeared to be related to the 
severity of maternal diabetes, as calcium concentration 
in the neonates was negatively related to maternal 
HbA1c levels[23]. 
It seems that hypocalcemia is rarely of clinical 
significance, particularly in case of GDM, unless other 
complications are associated[24]. 
The mechanism is still unclear but seems to involve 
an abnormal calcium phosphorus metabolism during 
pregnancy with a decrease in calcium and vitamin D 
concentrations especially during the third trimester. 
Some studies have reported an association between 
GDM and low maternal vitamin D status, particularly 
with poor blood glucose control. Conversely, there are 
growing evidences that women who develop GDM are 
more likely to be vitamin D deficient[25]. Other factors 
like prematurity and perinatal asphyxia can contribute 
to low calcium levels[26]. 
Therefore, there is no indication to screen healthy 
baby for hypocalcemia and hypomagnesemia. When 
treatment is indicated, it consists to give oral vitamin 
D supplements and calcium gluconate orally or 
intravenously (40-60 mg/kg per day) and magnesium 
treatment according to plasma level.
Hyperbilirubinemia: Hyperbilirubinemia is more 
frequently observed in infants born to diabetic 
mothers. It is not a serious complication if non-toxic 
levels are diagnosed and treated, which is usually 
the case. The risk of nuclear icterus, the severe 
form of hyperbilirubinemia, is not reported in cases 
of diabetes as being more frequent. In the HAPO 
study, hyperbilirubinemia was weakly associated with 
maternal blood glucose levels[8]. Polycythemia could be 
one of the reasons, but additional mechanisms, such 
as preterm birth, poor liver conjugation are likely to be 
involved.
Hematologic disorders 
It has been reported that infants of diabetic mothers 
may have polycythemia [hematocrit (Ht) higher than 
65%]. Mechanisms evoked are reduced transplacental 
oxygen transport to the fetus and increased fetal 
oxygen consumption due to fetal hyperinsulinism. 
This may lead to fetal hypoxia and increased levels of 
fetal erythropoietin. However, no consistent correlation 
between plasma erythropoietin level and polycythemia 
has been reported in human. Increased insulin 
and IGFs levels can also increase red blood cells 
production. A strong positive correlation between 
maternal β-hydroxybutyrate levels and polycythemia 
was observed in a small observational study[27].
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according to the severity and the extension of cardiac 
hypertrophy. Major septal hypertrophy can lead to 
subaortic stenosis and secondary mitral insufficiency. It 
is usually considered that heart hypertrophy resolves 
anatomically within few months. However, the long 
term effect of diabetic cardiomyopathy on heart 
function remains to be elucidated.
Cardiac malformations: Some data supports that 
GDM carries a small but significantly increased of 
congenital defects (ORs between 1.1 and 1.3), but 
it is much lower than in women with pregestational 
diabetes[37]. The malformations described are similar 
to those reported in pregestational diabetes, especially 
cardiovascular defects and anomalies involving the 
musculo-skeletal and central nervous systems[38,39].
The most commonly reported cardiac malformations 
include transposition of the great arteries, double 
outlet right ventricle, truncus arteriosus, hypoplastic 
left heart syndrome and ventricular septal defects[40].
Antenatal ultrasounds play an important role 
in monitoring fetal cardiac anatomy and function. 
Antenatal diagnosis of cardiac malformation is helpful 
to decide the place of birth when specific neonatal 
cardiologic care is needed. Babies of women with GDM 
should have an echocardiogram in the presence of 
clinical signs at birth associated with congenital heart 
malformations (cyanosis, murmur) or cardiomyopathy 
(heart failure).
Neurological impairments
Infants of diabetic mothers are prone to neurologic 
impairments, mainly due to perinatal asphyxia, birth 
traumas and metabolic disorders.
Perinatal asphyxia: Increased risk of perinatal 
asphyxia has been reported in diabetic pregnancies in 
a number of studies. The risks of perinatal asphyxia 
are increased in case of macrosomia, particularly 
when there is a shoulder dystocia[28,41]. Impaired fetal 
environment characterized by fetal hypoxia has also 
been evoked as a contributing factor.
However, in cases of GDM, the incidence of perinatal 
asphyxia, defined by a 5-min Apgar score < 7, was 
very low (1%-2%) in a study including more than a 
thousand neonates of GDM mothers[18]. In another 
study, umbilical arterial pH < 7.2 was about 15% in 
GDM group, comparable to the non-diabetic group[42]. 
In both studies, the incidence was not influenced by 
the treatment of maternal diabetes.
Metabolic disorders: Glucose is the main energy 
substrate for the brain. In newborns, hypoglycemia can 
lead to the situation where brain energy metabolism 
cannot be sustained. The consequences of low blood 
glucose levels depend on the availability of other 
substrates, such as lactate and ketone bodies also 
used by the brain to provide energy. These alternative 
substrates are not routinely measured, and the normal 
Normovolemic polycythemia seen in infants from 
diabetic mother can lead to hyperviscosity. Early 
symptoms are unspecific, feeding problems, plethoric 
aspect, acro-cyanosis, lethargy, hypotonia, respiratory 
distress, jitteriness and irritability, seizure (due to 
multiple cerebral infarcts), necrotizing enterocolitis, 
hyperbilirubinaemia and hypoglycemia have all been 
found associated. Polycythemia may also favor deep 
vessels thrombosis. Hypoglycemia may be aggravated 
in infants from diabetic mothers in case of polycythemia, 
due to increased glucose consumption by the increased 
red cell mass. Partial exchange transfusion with saline 
solution should be performed in symptomatic infants 
according to the formula (volume exchanged in mL): 
(Ht-55) x weight (kg) x 80/Ht.
Respiratory disorders
The rate and the risk of respiratory distress syndrome 
(RDS) in cases of GDM cannot be accurately established, 
due to insufficient precise data[28]. In a recent study 
from the French birth cohort in 2011, including 474 
614 births, the risk for neonatal respiratory disorders 
was slightly but significantly increased in case of GDM 
[OR adjusted on mother’s age and gestational age, 1.2 
(1.1-1.3)] (personal data not yet published).
It is generally recognized that, besides RDS, infants 
born to diabetic mothers are exposed to increased risk 
of transient tachypnea of the newborn. This is more 
likely to happen after caesarian section due to delayed 
reduction of alveolar fluid at birth and when the infants 
have macrosomia. This was clearly showed in infants 
of T1D mothers[29].
Diabetes, but also maternal body mass index (BMI), 
is associated with a higher risk of persistent pulmonary 
hypertension (PPH). However, other independent risk 
factors like macrosomia and caesarean deliveries 
might be in the causal pathway between diabetes, 
overweight and PPH[30].
Cardiac disorders
Hypertrophic cardiomyopathy: Fetuses exposed 
to maternal hyperglycemia and hyperinsulinism, are 
prone to develop hypertrophic cardiomyopathy. It 
primarily affects the interventricular septum, but can 
extend to the myocardium in more severe cases[31]. 
Myocardial hypertrophy has been reported in both 
pregestational diabetes and GDM with a wide range 
of frequencies (between 25% to 75% of infants born 
to diabetic mothers)[32,33]. The incidence was lower 
in case of pure GDM comparing to pregestational 
diabetes[34]. The most recent studies showed that good 
maternal glycemic control does not entirely prevent 
interventricular septum hypertrophy and minor fetal 
cardiac function impairment, regardless of the type 
of diabetes[35,36]. Although myocardial hypertrophy 
is associated with an overall decrease in ventricular 
compliance and an increase in contractility of the left 
and right ventricles, it is most often asymptomatic. It 
can sometimes lead to severe morbidity and mortality, 
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threshold values are unknown. Their availability also 
depends on the clinical and nutritional status of the 
infant. 
For infants presenting with clinical signs compatible 
with hypoglycemia, like apnoea, hypotonia, jitteriness, 
apathy, hypothermia, tremors and seizures, treatment 
must ensure that blood glucose levels remain above 
0.45 g/L (2.5 mmol/L). An IV bolus dose of glucose 
(150-200 mg/kg) should be administered urgently, 
followed by a constant rate infusion. It is necessary 
to check that thereafter blood glucose concentrations 
stabilize within normal ranges (20). In case of clinical 
signs, Cornblath et al[43] have suggested that the 
Whipple triad should be fulfilled: a low blood glucose 
concentration; signs consistent with hypoglycemia; and 
resolution of signs and symptoms after restoring blood 
glucose concentrations to normal values. Therefore, if 
symptoms persist despite adequate treatment, other 
causes should be investigated, since these symptoms 
are not specific.
Symptoms from hypocalcemia are similar to those 
observed in hypoglycemia, but usually present later, 
between 24-72 h of life[31]. Then, blood calcium con-
centration should also be measured in the presence of 
symptoms suggestive of hypocalcemia.
Brachial plexus injuries: The spinal cord is vulnerable 
to birth trauma with symptoms related to palsies of 
the brachial plexus. 
The most common type of brachial plexus injury, 
also called Erb’s palsy, involved the cervical roots 
C5 to C7. The infant presents with internally rotated 
arm and flexed wrist. The second most common 
type called total plexus palsy involves cervical roots 
C5-C8 and sometimes thoracic root T1. The infant 
presents with a flaccid and insensitive arm and with 
clawed hand. Paralysis of the hemi-diaphragm is also 
observed when phrenic nerve is involved, leading to 
respiratory insufficiency and requirement of mechanical 
ventilation[44].
Incidence of brachial plexus palsy in newborns 
of diabetic mothers is low, between 0.2% and 3%. 
As a consequence, the risk could not be accurately 
measured[28]. 
Poor suckling: It has been shown in the early nineties 
that maternal GDM may impair neonatal behavior, 
leading to lethargy and hypotonia related to delayed 
neural maturation. More recently, poorer suckling 
patterns were found at day 3 only among infants of 
insulin-managed GDM mothers, but not in the diet-
managed mothers[45]. This study confirmed some 
degree of neurologic immaturity during the early 
neonatal period.
 
Digestive impairment
Apart from the difficulties to feed because of poor 
suckling pattern, neonates of diabetic mothers may 
also exhibit neonatal small left colon, a cause of 
functional lower intestinal obstruction that can mimic 
Hirschsprung disease. The pathophysiology is unknown 
but it is significantly associated with maternal diabetes. 
The treatment is always conservative as long as 
intestinal perforation does not happen. Contrast enema 
is both diagnostic (abrupt transition zone at the splenic 
flexure) and curative, promoting the evacuation of 
meconium relieving the intestinal obstruction[46].
FACTORS THAT INFLUENCE THE SEVER-
ITY OF NEONATAL ADVERSE OUTCOME 
IN GDM 
The adverse neonatal outcomes described above are 
not constant in all cases but they are significantly influ­
enced by the quality of maternal care and by maternal 
health. Furthermore, most of these complications are 
more likely to happen in macrosomic infants.
Maternal conditions and neonatal outcomes
Impact of maternal blood glucose levels and 
pregestational T2D on neonatal outcomes: 
Perinatal death, malformations and prematurity are 
mainly influenced by maternal glucose levels. As 
discussed above, there is also a linear relationship 
between glucose maternal level and the frequency of 
macrosomia[8]. Furthermore, the analysis of the risk 
of fetal malformation and perinatal death in case of 
GDM shows that undiagnosed pre-pregnancy T2D 
has a substantial impact on these serious perinatal 
complications.
There is a relationship between the malformation 
rate and maternal fasting blood glucose level[39,47]. This 
risk also increases with maternal BMI, and when GDM 
is diagnosed during early pregnancy[48,49]. Most major 
malformations occur very early in gestation during 
the embryonic stage. In diabetic pregnancies, they 
are attributable to unstable periconceptional glycemia. 
Maternal hyperglycemia results in excess glucose 
metabolism in the developing embryo that may alter 
various molecular chain reactions: (1) altered cell lipid 
metabolism, notably the production of prostaglandin 
E2 involved in the patency of the ductus arteriosus 
in utero[50]; (2) high glucose levels induce an excess 
production of reactive oxygen species which has been 
shown to cause oxidative stress and subsequently 
increase the risk for fetal malformations, notably 
neural tube defect[51]; and also (3) high glucose 
levels induce the activation of many proteins involved 
in apoptotic cell death, including members of the 
caspase families[52]. Although data on the molecular 
basis of diabetic embryopathy have improved during 
the last years, mechanisms are still incompletely 
understood[53].
These clinical and physiopathologic data suggest 
that the increased risk of congenital defects in GDM 
reported in some studies is likely to be related to the 
inclusion of women with undiagnosed T2D in the GDM 
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groups[54].
Unlike in pregestational diabetes, the increased 
rate of fetal deaths in the 2nd and 3rd trimesters of 
pregnancy is debatable in cases of GDM[55,56]. In a 
large cohort study, the rate of mortality was 16.2/1000 
in the GDM group vs 12.5/1000 in the general 
population. Six weeks after delivery, women diagnosed 
with GDM were re­classified by a post­partum glucose 
tolerance test. Women having diabetes on post-
partum test were considered as “newly presenting 
T2D”. When those women were excluded from the 
GDM group, perinatal mortality was 8.9/1000 in the 
“true” GDM group, which was similar to the general 
population. Mortality was the highest in the groups 
with T2D diagnosed before and after pregnancy 
(respectively, 39.1/1000 and 56.2/1000)[57]. These 
data demonstrated that the increased risk of perinatal 
death reported in case of GDM in some studies, seems 
to be attributable to undiagnosed T2D.
Prematurity is one of the leading causes of neonatal 
death. As discuss above, higher maternal glucose 
levels were observed in case of prematurity in GDM 
pregnancies. Furthermore, one of the main causes of 
induced preterm delivery is maternal pre-eclampsia 
which is more commonly associated with T2D preg-
nancies[58].
Impact of maternal obesity in the complications 
of GDM: Maternal obesity is associated with worse 
perinatal outcome even in glucose-tolerant women. 
Macrosomia is the main complication reported in 
overweight or obese women, independently of 
diabetes[59-62]. It is well recognized that neonates born 
to obese women, even if normal glucose tolerant, have 
increased fat mass[63]. As in GDM, increased adiposity 
at birth is related to maternal excess of glucose and 
lipids availability, and placental transfer to the fetus[11].
The risk of fetal and infant deaths are two to three 
times greater for women with preconceptional obesity, 
after excluding pregnancies affected by congenital 
anomalies or pregestational diabetes[64]. It was recently 
showed that even modest increases in maternal BMI 
were associated with increased risk of fetal death, 
stillbirth, and neonatal, perinatal, and infant death. 
The relative risk per 5-unit increase in maternal BMI 
ranged from 1.15 to 1.24[65]. Maternal obesity is 
also associated with an increased risk of a range of 
structural anomalies, with the higher risk for neural 
tube defects[66,67]. It is interesting to note that the risk 
of particular malformations such as omphalocele and 
diaphragmatic hernia is increased in obese pregnant 
women, but not in case of diabetes[68,69]. 
There is a tight link between maternal obesity 
and diabetes in pregnancy. Indeed, the risk of GDM 
increases with maternal BMI[70]. The overall population-
attributable fraction of GDM related to overweight was 
estimated at 46.2%[71]. 
The benefit effect of treatment of diabetes on 
neonatal outcomes is lower in obese women, even 
if targeted levels of glycemic control are achieved. 
Furthermore, when GDM is untreated or poorly 
controlled, overweight and obese women have a 
higher risk of poor neonatal outcome, compared to 
normal weight GDM women[42,72].
The combination of GDM and obesity shows a 
greater impact on pregnancy outcomes than either 
GDM or obesity alone. This cumulative risk was 
shown for macrosomia, newborn percent body fat and 
birth trauma[73]. It was also reported for a composite 
neonatal outcome (BW > 4000 g, birth trauma, 
shoulder dystocia, hypoglycemia, or jaundice)[74].
Effects of macrosomia on neonatal outcomes
It has long been reported that the delivery of 
macrosomic infants is associated with a higher risk 
for adverse neonatal morbidity such as birth injury, 
respiratory distress and hypoglycemia. Macrosomia 
(BW > 4500 g), regardless of the cause, is also in itself 
a risk factor for asphyxia and perinatal death[75].
Macrosomia increases the risk of shoulder dystocia, 
regardless of the cause. In the study by Zhang et al[75], 
the risk of birth injury was the highest for infants with 
a birth weight 4500-4999 g and ≥ 5000 g, [ORs 2.4 
(2.2-2.5) and 3.5 (3.0-4.2), respectively].
In the case of GDM, there is a particularly high risk 
of respiratory distress in newborns with a BW ≥ 4000 
g, compared to those with a BW of less than 4000 g [OR 
= 3.1 (1.11-8.65)][76]. In the other study, the risk of 
respiratory complications increased with increasing BW 
≥ 4000 g, irrespective of maternal diabetic status[22]. 
Furthermore, it seems that clinically significant 
hypertrophic cardiomyopathy without concomitant 
fetal macrosomia is rarely observed[40].
The analysis of the data collected by the HAPO 
study showed that neonatal hypoglycemia was 
strongly related to elevated cord C-peptide levels. High 
C-peptide levels are related to the importance of fetal 
hyperinsulinemia that favors fetal excess of growth. 
Therefore, infants with excessive size at birth are prone 
to develop hypoglycemia[16]. It was shown that when 
BW was ≥ 4000 g the risk of hypoglycemia increased, 
but the risk was higher when BW ≥ 4000 g was 
associated with maternal GDM[76]. In another study, 
the risk of hypoglycemia increased with increasing BW, 
irrespective of maternal diabetic status[77].
SIZE OF THE BURDEN IN LOW INCOME 
COUNTRIES
The prevalence of risk factors for diabetes during 
pregnancy are increasing all around the world because 
of increasing incidence of T2D and obesity and the shift 
of age at onset of diabetes to younger age groups. 
T2D is an occult disease that can remain undiagnosed, 
especially in young women of reproductive age. A 
recent study reported an estimated global prevalence 
of hyperglycemia in pregnancy worldwide of 170/1000 
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live births in 2013. A majority of cases occurred in low 
and middle income countries (91.6%). The prevalence 
varies widely around the world. The South-East Asia 
region had the highest prevalence with 23% of live 
births, followed by the Middle East and North Africa 
region with 22%[78].
A community-based prospective program in India, 
with universal screening for GDM, showed that the 
prevalence of GDM was 13.9%. The frequency varied 
widely across urban, semi-urban and rural areas, 
respectively 17.8%, 13.8% and 9.9%. The prevalence 
also varied according to maternal BMI. For BMI ≥ 
25 mg/m2, the incidence was up to 28.4%, 23.8% 
and 16.1% in urban, semi-urban and rural areas, 
respectively[79].
A recent analysis of data from World Health Orga-
nization (WHO)’s Global Survey on maternal and perinatal 
outcomes in 23 developing countries described the 
prevalence of macrosomia, one of the main com-
plications of maternal diabetes and obesity[80]. There 
was a large variation in the prevalence of babies with 
BW ≥ 4 kg, ranging from 0.5% in India, to 15% in 
Algeria. Maternal diabetes and increased gestational 
BMI were significantly associated with macrosomia 
in all regions. For example, in Algeria, where 15% of 
the babies had a BW ≥ 4 kg, 25% of the mothers 
were obese (BMI ≥ 30 kg/m2). In in Latin America 
countries, frequency of maternal obesity was more 
than 30% (Argentina, Mexico, and Paraguay). 
It can then be estimated that the burden of neo-
natal complications is higher in developing countries 
than in high-income countries, because of the high 
incidence of maternal hyperglycemia and the absence 
of screening and treatment of maternal diabetes, and 
finally because of substandard neonatal care. This is 
probably even worst within the rural areas, because of 
limited financial and human resources.
CONCLUSION
It is indisputable that diabetes during pregnancy 
exposes the fetus and the neonates to increased 
adverse outcomes. These risks mainly depend on 
maternal health condition. Thus, awareness of maternal 
health prior and during pregnancy is essential to 
pediatricians to anticipate the severity of neonatal 
adverse outcome. Health systems in low income 
countries are often insufficiently structured to provide 
adequate screening and care to diabetic mothers. Such 
situations seriously increase the burden of adverse fetal 
and neonatal outcomes, probably still underestimated.
The current definition of GDM does not allow 
identifying pregestational diabetes from true GDM. 
The WHO recently proposed new criteria for the 
diagnosis and definition of hyperglycemia first de-
tected in pregnancy which distinguishes the more 
serious diabetes in pregnancy from GDM[81]. This is a 
considerable advance as we say that risks of serious 
complications for fetuses and the neonates are much 
higher in true diabetes than in GDM. This will help 
to better understand the burden of hyperglycemia 
in pregnancy and its relationship with the growing 
prevalence of T2D. This will also probably allow in the 
future to determine precisely the risks linked to GDM 
compared to those linked to T2D. Such distinction 
will subsequently help better identifying risks in the 
neonatal period, but also later in life. Indeed, offspring 
of diabetic and obese women, or macrosomic infants, 
are more likely to be obese and to have diabetes and 
cardiovascular diseases in adulthood[3,4]. These long-
term consequences of diabetes in pregnancy are going 
to be the burden of further generations. 
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